Drug General Information
Drug ID
D05XLO
Former ID
DCL000134
Drug Name
INCB13739
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 2a [522347]
Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Phase 2 [522347]
Company
Incyte
Structure
Download
2D MOL

3D MOL

Formula
C6H5AsO
Canonical SMILES
C1=CC=C(C=C1)[As]=O
InChI
1S/C6H5AsO/c8-7-6-4-2-1-3-5-6/h1-5H
InChIKey
BQVCCPGCDUSGOE-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Corticosteroid 11-beta-dehydrogenase, isozyme 1 Target Info Inhibitor [551127]
KEGG Pathway Steroid hormone biosynthesis
Metabolism of xenobiotics by cytochrome P450
Metabolic pathways
Chemical carcinogenesis
NetPath Pathway IL1 Signaling Pathway
FSH Signaling Pathway
PathWhiz Pathway Steroidogenesis
Reactome Glucocorticoid biosynthesis
WikiPathways Prostaglandin Synthesis and Regulation
Metabolism of steroid hormones and vitamin D
Glucocorticoid & Mineralcorticoid Metabolism
References
Ref 522347ClinicalTrials.gov (NCT00698230) Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics. U.S. National Institutes of Health.
Ref 551127Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.